SG11201907084VA - Pharmaceutical compositions for combination therapy - Google Patents
Pharmaceutical compositions for combination therapyInfo
- Publication number
- SG11201907084VA SG11201907084VA SG11201907084VA SG11201907084VA SG11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- loos
- pct
- danel
- leonard
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305213 | 2017-02-24 | ||
| PCT/EP2018/054588 WO2018154081A1 (en) | 2017-02-24 | 2018-02-23 | Pharmaceutical compositions for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907084VA true SG11201907084VA (en) | 2019-09-27 |
Family
ID=58231557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907084VA SG11201907084VA (en) | 2017-02-24 | 2018-02-23 | Pharmaceutical compositions for combination therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11590108B2 (ru) |
| EP (1) | EP3585384A1 (ru) |
| JP (1) | JP2020510651A (ru) |
| KR (1) | KR102633249B1 (ru) |
| CN (1) | CN110418641A (ru) |
| AU (1) | AU2018223976B2 (ru) |
| BR (1) | BR112019017314A2 (ru) |
| CA (1) | CA3051977A1 (ru) |
| EA (1) | EA201991990A1 (ru) |
| IL (1) | IL268708B (ru) |
| MX (1) | MX2019009909A (ru) |
| PH (1) | PH12019501820A1 (ru) |
| SG (1) | SG11201907084VA (ru) |
| WO (1) | WO2018154081A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220133666A1 (en) * | 2016-03-31 | 2022-05-05 | Genfit | Methods of treatment of cholestatic diseases |
| CA3018132C (en) * | 2016-03-31 | 2024-02-13 | Genfit | Use of elafibranor in the treatment of a cholestatic disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20030329A1 (es) | 2001-08-08 | 2003-05-12 | Takeda Chemical Industries Ltd | Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo |
| FR2841900B1 (fr) | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
| PL2504005T3 (pl) | 2009-11-26 | 2014-03-31 | Genfit | Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby |
| ES2633766T3 (es) * | 2011-10-28 | 2017-09-25 | Lumena Pharmaceuticals Llc | Inhibidores de reciclaje de ácido biliar para el tratamiento de enfermedades de hígado colestático pediátrico |
| KR20160132489A (ko) * | 2014-03-21 | 2016-11-18 | 토비라 쎄라퓨틱스, 인크. | 섬유증 치료용 세니크리바이록 |
| RU2723559C2 (ru) * | 2014-09-12 | 2020-06-16 | Тобира Терапьютикс, Инк. | Комбинированная терапия с применением препарата ценикривирок для лечения фиброза |
| CA2998509A1 (en) * | 2015-09-16 | 2017-03-23 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| CA3018132C (en) * | 2016-03-31 | 2024-02-13 | Genfit | Use of elafibranor in the treatment of a cholestatic disease |
| MX2018012285A (es) * | 2016-04-11 | 2019-02-07 | Genfit | Metodos de tratamiento para enfermedades colestasicas y fibroticas. |
| JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
| SG11201906041QA (en) * | 2017-01-27 | 2019-08-27 | Genfit | Pharmaceutical compositions for combination therapy |
-
2018
- 2018-02-23 JP JP2019546127A patent/JP2020510651A/ja active Pending
- 2018-02-23 BR BR112019017314A patent/BR112019017314A2/pt not_active Application Discontinuation
- 2018-02-23 MX MX2019009909A patent/MX2019009909A/es unknown
- 2018-02-23 EP EP18705945.6A patent/EP3585384A1/en not_active Withdrawn
- 2018-02-23 EA EA201991990A patent/EA201991990A1/ru unknown
- 2018-02-23 AU AU2018223976A patent/AU2018223976B2/en active Active
- 2018-02-23 WO PCT/EP2018/054588 patent/WO2018154081A1/en unknown
- 2018-02-23 CN CN201880013686.4A patent/CN110418641A/zh active Pending
- 2018-02-23 US US16/485,025 patent/US11590108B2/en active Active
- 2018-02-23 KR KR1020197027007A patent/KR102633249B1/ko active IP Right Grant
- 2018-02-23 CA CA3051977A patent/CA3051977A1/en active Pending
- 2018-02-23 SG SG11201907084VA patent/SG11201907084VA/en unknown
-
2019
- 2019-08-06 PH PH12019501820A patent/PH12019501820A1/en unknown
- 2019-08-14 IL IL268708A patent/IL268708B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190388394A1 (en) | 2019-12-26 |
| MX2019009909A (es) | 2019-10-14 |
| CA3051977A1 (en) | 2018-08-30 |
| IL268708A (en) | 2019-10-31 |
| WO2018154081A1 (en) | 2018-08-30 |
| JP2020510651A (ja) | 2020-04-09 |
| BR112019017314A2 (pt) | 2020-04-14 |
| AU2018223976B2 (en) | 2023-08-17 |
| KR20190119097A (ko) | 2019-10-21 |
| CN110418641A (zh) | 2019-11-05 |
| US11590108B2 (en) | 2023-02-28 |
| AU2018223976A1 (en) | 2019-09-05 |
| KR102633249B1 (ko) | 2024-02-02 |
| EA201991990A1 (ru) | 2020-04-07 |
| PH12019501820A1 (en) | 2020-09-14 |
| IL268708B (en) | 2022-05-01 |
| EP3585384A1 (en) | 2020-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201909168VA (en) | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor | |
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201808540SA (en) | Methods of treatment for cholestatic and fibrotic diseases |